The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer
Open accessAbstract
FOXM1 is frequently overexpressed in cancer, but this has not been studied in a comprehensive manner. We utilized genotype-tissue expression (GTEx) normal and The Cancer Genome Atlas (TCGA) tumor data to define FOXM1 expression, including its isoforms, and to determine the genetic alterations that promote FOXM1 expression in cancer. Additionally, we used human fallopian tube epithelial (FTE) cells to dissect the role of Retinoblastoma (Rb)-E2F and Cyclin E1 in FOXM1 regulation, and a novel human embryonic kidney cell (HEK293T) CRISPR FOXM1 knockout model to define isoform-specific transcriptional programs. FOXM1 expression, at the mRNA and protein level, was significantly elevated in tumors with FOXM1 amplification, p53 inactivation, and Rb-E2F deregulation. FOXM1 expression was remarkably high in testicular germ cell tumors (TGCT), high-grade serous ovarian cancer (HGSC), and basal breast cancer (BBC). FOXM1 expression in cancer was associated with genomic instability, as measured using aneuploidy signatures. FTE models confirmed a role for Rb-E2F signaling in FOXM1 regulation and in particular identified Cyclin E1 as a novel inducer of FOXM1 expression. Among the three FOXM1 isoforms, FOXM1c showed the highest expression in normal and tumor tissues and cancer cell lines. The CRISPR knockout model demonstrated that FOXM1b and FOXM1c are transcriptionally active, while FOXM1a is not. Finally, we were unable to confirm the existence of a FOXM1 auto-regulatory loop. This study provides significant and novel information regarding the frequency, causes, and consequences of elevated FOXM1 expression in human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“Cell Line Encyclopedia (CCLE) data [35].”
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546
Toil enables reproducible, open source, big biomedical data analyses
Vivian, J., Rao, A. A., Nothaft, F. A., Ketchum, C., Armstrong, J., Novak, A., Pfeil, J., Narkizian, J., Deran, A. D., Musselman-Brown, A., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3772 · Cited by 1,365
The Rb/E2F pathway: expanding roles and emerging paradigms
Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153 · cited 1×
“Cyclin E1/CDK2 complexes inactivate Rb by phosphorylation, leading to E2F activation [58], which may mechanistically explain why Cyclin E1 induces FOXM1 expression, but this requires testing.”
BackgroundModeling High-Grade Serous Ovarian Carcinogenesis from the Fallopian Tube
Karst, A. M., Levanon, K., & Drapkin, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017300108 · Cited by 280 · cited 1×
“To validate these findings in a more relevant genetic context and precursor cell model for HGSC, we utilized hTERT-immortalized fallopian tube epithelial (FTE) cells [48,49].”
MethodTassi, R. A., Todeschini, P., Siegel, E. R., Calza, S., Cappella, P., Ardighieri, L., Cadei, M., Bugatti, M., Romani, C., Bandiera, E., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0536-y · Cited by 67
Cited by
Zhang, W., Klinkebiel, D., Barger, C. J., Pandey, S., Guda, C., Miller, A., Akers, S. N., Odunsi, K., & Karpf, A. R. (2020) · Cancers · doi:10.3390/cancers12030764 · Cited by 277
Self-citationThe bone microenvironment invigorates metastatic seeds for further dissemination
Zhang, W., Bado, I. L., Hu, J., Wan, Y.-W., Wu, L., Wang, H., Gao, Y., Jeong, H.-H., Xu, Z., Hao, X., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.011 · Cited by 260
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
Bery, N., Miller, A., & Rabbitts, T. (2020) · Nature Communications · doi:10.1038/s41467-020-17022-w · Cited by 132
Ribeiro, R., Macedo, J. C., Costa, M., Ustiyan, V., Shindyapina, A. V., Tyshkovskiy, A., Gomes, R. N., Castro, J. P., Kalin, T. V., Vasques-Nóvoa, F., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00209-9 · Cited by 60
Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation
Luo, G., Lin, X., Vega-Medina, A., Xiao, M., Li, G., Wei, H., Velázquez-Martínez, C. A., & Xiang, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01069 · Cited by 56
Metadata
- Authors
- Barger, C. J., Branick, C., Chee, L., & Karpf, A. R.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-02-21
- Volume
- 11
- Issue
- 2
- Pages
- 251
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2917187119
- Cited by
- 209
- References
- 9
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.